ArticleBreast (Edinburgh, Scotland)2026
Identifying pre-treatment risk factors for cancer-related cognitive decline in patients with breast cancer.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore pre-treatment risk factors for cognitive decline in patients with breast cancer using a machine learning approach applied to a comprehensive multimodal clinical, biological, and neuroimaging dataset.
methodsSixty-seven women with early breast cancer were assessed at diagnosis (T0), 8 months (T1), and 17 months after diagnosis (T2). Cognitive decline was defined using the Reliable Change Index. Patients were classified as showing no decline or decline at either follow-up. Five feature sets were evaluated: (1) patient characteristics, treatment, and psychosocial measures; (2) inflammatory and neural health markers, (3) structural brain volumes, (4) resting-state functional MRI connectivity, and (5) diffusion MRI measures. Random forest models were first trained on feature set 1, then sequentially combined with sets 2-5 to explore their additive predictive value. Each model underwent standardized preprocessing, recursive feature selection of the top 6 predictors, and tuning before random forest classification. A final composite model was constructed by pooling the six top predictors from each feature set to assess potential complementary multimodal information. Feature contributions were examined using SHAP values.
resultsOf 67 patients, 33 (49%) experienced cognitive decline following treatment. Models achieved prediction accuracies of 76%, improving up to 81% when MRI measures and/or serum markers were included. Key baseline predictors of cognitive decline included more aggressive subtypes, planned systemic therapy, perceived stress, and limited cognitive and brain reserve.
conclusionMachine learning explored potential pre-treatment risk factors for cancer-related cognitive decline in patients with breast cancer. These findings highlight potential risk factors that could support risk-stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.